|Brand name(s), other common name(s)||Zydelig®|
|Drug type||Phosphoinositide 3-kinase (PI3K) delta inhibitor|
|How the drug is given||By mouth|
Idelalisib is FDA approved to treat patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. It is also approved to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) or relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
Side effects needing medical attention:Diarrhea, fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills, rash, neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations.
Idelalisib is being approved with a Boxed Warning alerting patients and healthcare professionals of the following fatal and serious adverse reactions: hepatotoxicity (liver damage caused by a drug), severe diarrhea or colitis, pneumonitis, and intestinal perforation.